15 July 2021

Contract manufacturing agreement signed for production of new pediatric treatment for schistosomiasis

Today, 15 July 2021, it was announced that Pediatric Praziquantel Consortium partner, Merck, has entered into a contract manufacturing agreement with Universal Corporation Ltd. in Kenya.

The agreement is for the large-scale production of the Consortium’s new pediatric medication to treat schistosomiasis, once registered. The collaboration with Universal follows on from the manufacturing activities led by Consortium partner Farmanguinhos and includes the establishment of extensive production capacities in Nairobi for the future provision of the treatment in endemic countries in Africa.

The establishment of local African production marks an important milestone for the project. Indeed, it adheres to key requirements of the World Health Organization 2030 NTD Road Map and contributes to several of the United Nations’ Sustainable Development Goals. It will also help ensure that any gaps between the Consortium’s and the endemic communities’ definition of a viable and affordable treatment will be bridged, ultimately allowing for equitable access to the treatment once available.  

Read the full press release on the Merck website here.